Use of the Oncotype DX™ 21-Gene Assay to Guide Adjuvant Decision Making in Early-Stage Breast Cancer

被引:0
作者
Alison K. Conlin
Andrew D. Seidman
机构
[1] Memorial Sloan Kettering Cancer Center,Breast Cancer Medicine Service
来源
Molecular Diagnosis & Therapy | 2007年 / 11卷
关键词
Breast Cancer; Tamoxifen; National Comprehensive Cancer Network; National Comprehensive Cancer Network; Recurrence Score;
D O I
暂无
中图分类号
学科分类号
摘要
The decision to use adjuvant chemotherapy in patients with early stage breast cancer involves the consideration of many factors that traditionally rely heavily on tumor size and lymph node involvement and a limited set of biologic characteristics such as estrogen receptor and HER2 expression. Overtreatment with cytotoxic chemotherapy is a significant concern among patients and physicians. Using the currently accepted guidelines it has been estimated that a large percentage of patients receiving chemotherapy for low-risk breast cancers may be overtreated. Gene expression profiling is a new technology being developed to help improve risk stratification of patients and to predict outcomes. The Oncotype DX™ assay is one example of a gene expression profile validated in women with lymph node-negative, estrogen receptor-expressing breast cancer. This assay and others aim to help improve risk classification and recurrence prediction and, therefore, optimize selection of patients for adjuvant chemotherapy.
引用
收藏
页码:355 / 360
页数:5
相关论文
共 109 条
[1]  
Parkin DM(2005)Global cancer statistics, 2002 CA Cancer J Clin 55 74-108
[2]  
Bray F(2006)Trends in breast cancer by race and ethnicity: update 2006 CA Cancer J Clin 56 168-83
[3]  
Ferlay J(2005)Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials Lancet 365 1687-717
[4]  
Smigal C(2005)Effect of screening and adjuvant therapy on mortality from breast cancer N Engl J Med 353 1784-92
[5]  
Jemal A(2006)Additional common inputs for analyzing impact of adjuvant therapy and mammography on U.S. mortality J Natl Cancer Inst Monogr 36 26-9
[6]  
Ward E(1983)Relation of number of positive axillary nodes to the prognosis of patients with primary breast cancer: an NSABP update Cancer 52 1551-7
[7]  
Berry DA(1989)Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases Cancer 63 181-7
[8]  
Cronin KA(1995)Biologic and clinicopathologic factors as indicators of specific relapse types in node negative breast cancers J Clin Oncol 13 697-704
[9]  
Plevritis SK(1994)Relationship of patient age to pathological features of tumour and prognosis for patients with stage I or II breast cancers J Clin Oncol 12 888-94
[10]  
Cronin KA(1993)Age as a prognostic factor in premenopausal breast cancer Lancet 341 1039-43